Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
RCM R1 RCM $9.61 -0.1 (-1.03%) 06:39 02/22/19 02/22 06:39 02/22/19 06:39 Earnings	R1 RCM sees FY19 revenue $1.15B-$1.25B, consensus $1.19B » Sees FY19: GAAP operating… Sees FY19: GAAP operating income of $50M-$80M; Adjusted EBITDA of $145M-$165M. FY19 EPS consensus (6c). 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb
RCM R1 RCM $9.61 -0.1 (-1.03%) 06:38 02/22/19 02/22 06:38 02/22/19 06:38 Earnings	R1 RCM reports Q4 EPS (10c), consensus (11c) » Reports Q4 revenue… Reports Q4 revenue $262.9M, consensus $264.48M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb

Over a month ago
RCM R1 RCM $8.51 (0.00%) 08:04 02/08/19 02/08 08:04 02/08/19 08:04 Hot Stocks	R1 RCM to build technology, innovation center in Salt Lake City » R1 RCM announced plans to… R1 RCM announced plans to build the R1 Technology and Innovation Center in Salt Lake City, Utah in collaboration with Intermountain Healthcare. Scheduled to open in May, the 30,000 square foot facility will be used to evaluate patient needs, test product concepts and elevate creativity and design, tackling some of the biggest problems faced by patients and healthcare organizations. R1 expects adoption of technologies such as AI and RPA, or robotic process automation, in the revenue cycle to play a role in helping healthcare providers improve their operations. Along with the development of RCM solutions, the center will also feature a virtual revenue cycle model office, serve as a client experience center and support the growing tech community in Utah. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Feb
HEXO HEXO Corp $5.26 0.01 (0.19%) , RCM R1 RCM $7.96 0.1 (1.27%) … 08:30 01/31/19 01/31 08:30 01/31/19 08:30 Options	Five new option listings on January 31st » New option listings for… New option listings for January 31st include Hexo Corporation (HEXO), RCM Technologies (RCM), Proshares Ultrapro Short Communication Serv Select Sector (SCOM), Proshares Ultrapro Communication Services Select Sector (UCOM), and SPDR S&P Health Care Equipment (XHE). HEXO HEXO Corp $5.26 0.01 (0.19%) RCM R1 RCM $7.96 0.1 (1.27%) SCOM Sharps Compliance Corp $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
STZ Constellation Brands $164.10 -0.03 (-0.02%) , EA Electronic Arts $90.68 -1.82 (-1.97%) … 10:17 01/22/19 01/22 10:17 01/22/19 10:17 Initiation	Fly Intel: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Constellation Brands (STZ) initiated with an Overweight at Atlantic Equities. 2. Take-Two (TTWO) initiated with a Buy at Deutsche Bank, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Hold. 3. Insys Therapeutics (INSY) initiated with an Overweight at Cantor Fitzgerald. 4. Heico (HEI) initiated with a Buy at Vertical Research. 5. R1 RCM (RCM) initiated with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. STZ Constellation Brands $164.10 -0.03 (-0.02%) EA Electronic Arts $90.68 -1.82 (-1.97%) TTWO Take-Two $107.79 -0.45 (-0.42%) ATVI Activision Blizzard $47.38 -1.26 (-2.59%) INSY Insys Therapeutics $4.45 0.03 (0.68%) HEI Heico $79.07 -1.23 (-1.53%) RCM R1 RCM $8.17 -0.15 (-1.80%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	24 Jan 05 Feb 06 Feb 12 Feb 18 Feb 25 Feb

RCM R1 RCM $8.32 0.16 (1.96%) 07:37 01/22/19 01/22 07:37 01/22/19 07:37 Initiation	R1 RCM initiated at KeyBanc » R1 RCM initiated with an… R1 RCM initiated with an Overweight at KeyBanc. KeyBanc analyst Donald Hooker started R1 RCM with an Overweight rating and $10 price target as a way for investors to play what he expects will be an increasing trend of revenue cycle outsourcing by U.S. health systems. The analyst believes R1 RCM is a beat-and-raise story, benefiting from low consensus expectations and a large $80B-plus TAM. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
RCM R1 RCM $7.96 0.44 (5.85%) 09:00 01/07/19 01/07 09:00 01/07/19 09:00 Recommendations	R1 RCM analyst commentary at Baird » R1 RCM designated as a… R1 RCM designated as a Fresh Pick at Baird. Baird analyst Matthew Gillmor designated R1 RCM as a Fresh Pick ahead of the company's presentation at the JP Morgan conference later this week. He believes it is likely the company will provide 2019 EBITDA guidance in-line with to ahead of Street expectations and thinks there could be a positive update with respect to its 2020 outlook. Gillmor reiterated his Outperform rating and $11 price target on R1 RCM shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan

Over a quarter ago
RCM R1 RCM $8.71 -0.31 (-3.44%) 07:29 12/10/18 12/10 07:29 12/10/18 07:29 Initiation	R1 RCM initiated at Citi » R1 RCM initiated with a… R1 RCM initiated with a Buy at Citi. Citi analyst Stephanie Demko started R1 RCM with a Buy rating and $20 price target. The company operates as the largest independent end-to-end revenue cycle management provider in the U.S., and is well positioned to benefit from growing demand for provider-facing information technology, Demko tells investors in a research note. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
RCM R1 RCM $7.77 -0.38 (-4.66%) 07:16 11/07/18 11/07 07:16 11/07/18 07:16 Earnings	R1 RCM sees FY18 revenue $850M-$900M, consensus $859.5M » Subject to finalization… Subject to finalization of purchase accounting for the Intermedix acquisition, for 2018, R1 expects to generate: Revenue of between $850 million and $900 million; GAAP operating loss of $30 million to $50 million; Adjusted EBITDA of $50 to $55 million. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Nov
RCM R1 RCM $7.77 -0.38 (-4.66%) 07:16 11/07/18 11/07 07:16 11/07/18 07:16 Earnings	R1 RCM reports Q3 EPS (17c), consensus (16c) » Reports Q3 revenue… Reports Q3 revenue $250.4M, consensus $240.08M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Nov

On The Fly

News and insights, exclusive to thefly.com

16:32	Stifel starts Amarin with Buy rating, sees 'robust' growth for Vascepa»
15:06	Bank stocks sit out rally, mirroring concern for broader economy»
13:33	Notable companies reporting after market close»
10:41	Goldman joins seven others in downgrading Biogen on Alzheimer's failure»
10:12	Fly Intel: Top five analyst initiations»

View all On The Fly Stories »

Upcoming
Events (10)

ALIT	Alight - ALIT
	European Financials Conference
BKH ...	West Coast Utilities Conference
	Annual Transports & Industrials Conference
	Financials Conference 2019
	Domopalooza 2019
	DCAT Week 2019
	London Oil & Gas Conference
	Food Enforcement and Compliance Conference
	Enterprise Connect Conference 2019

View all of today’s events »

Today’s
Syndicate (6)

LEVI	IPO
EQH	Secondary
FTDR	Secondary
LQDA	Secondary
TGLS	Secondary
CBMG	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial